Response  ||| S:0 E:9 ||| NN
loss  ||| S:9 E:14 ||| NN
and  ||| S:14 E:18 ||| CC
development  ||| S:18 E:30 ||| NN
of  ||| S:30 E:33 ||| IN
neutralizing  ||| S:33 E:46 ||| JJ
antibodies  ||| S:46 E:57 ||| NNS
during  ||| S:57 E:64 ||| IN
long-term  ||| S:64 E:74 ||| JJ
treatment  ||| S:74 E:84 ||| NN
with  ||| S:84 E:89 ||| IN
romiplostim  ||| S:89 E:101 ||| NN
in  ||| S:101 E:104 ||| IN
patients  ||| S:104 E:113 ||| NNS
with  ||| S:113 E:118 ||| IN
immune  ||| S:118 E:125 ||| JJ
thrombocytopenia ||| S:125 E:141 ||| NN
:  ||| S:141 E:143 ||| :
a  ||| S:143 E:145 ||| DT
case  ||| S:145 E:150 ||| NN
series  ||| S:150 E:157 ||| NN
Immune  ||| S:157 E:164 ||| NNP
thrombocytopenia  ||| S:164 E:181 ||| NNS
( ||| S:181 E:182 ||| -LRB-
ITP ||| S:182 E:185 ||| NNP
)  ||| S:185 E:187 ||| -RRB-
is  ||| S:187 E:190 ||| VBZ
an  ||| S:190 E:193 ||| DT
autoimmune  ||| S:193 E:204 ||| JJ
disorder  ||| S:204 E:213 ||| NN
characterized  ||| S:213 E:227 ||| VBN
by  ||| S:227 E:230 ||| IN
low  ||| S:230 E:234 ||| JJ
platelet  ||| S:234 E:243 ||| NN
counts  ||| S:243 E:250 ||| VBZ
resulting  ||| S:250 E:260 ||| VBG
from  ||| S:260 E:265 ||| IN
both  ||| S:265 E:270 ||| DT
immune-mediated  ||| S:270 E:286 ||| JJ
platelet  ||| S:286 E:295 ||| JJ
destruction  ||| S:295 E:307 ||| NN
and  ||| S:307 E:311 ||| CC
inappropriate  ||| S:311 E:325 ||| JJ
bone  ||| S:325 E:330 ||| NN
marrow  ||| S:330 E:337 ||| VBZ
platelet  ||| S:337 E:346 ||| JJ
production ||| S:346 E:356 ||| NN
.  ||| S:356 E:358 ||| .
Therefore ||| S:358 E:367 ||| RB
,  ||| S:367 E:369 ||| ,
in  ||| S:369 E:372 ||| IN
ITP  ||| S:372 E:376 ||| NNP
patients  ||| S:376 E:385 ||| FW
failing  ||| S:385 E:393 ||| FW
immunosuppressants ||| S:393 E:411 ||| FW
/ ||| S:411 E:412 ||| FW
splenectomy ||| S:412 E:423 ||| FW
,  ||| S:423 E:425 ||| ,
an  ||| S:425 E:428 ||| DT
alternative  ||| S:428 E:440 ||| JJ
approach  ||| S:440 E:449 ||| NN
is  ||| S:449 E:452 ||| VBZ
to  ||| S:452 E:455 ||| TO
enhance  ||| S:455 E:463 ||| VB
platelet  ||| S:463 E:472 ||| JJ
production  ||| S:472 E:483 ||| NN
stimulating  ||| S:483 E:495 ||| VBG
thrombopoiesis ||| S:495 E:509 ||| NNS
.  ||| S:509 E:511 ||| .
Studies  ||| S:511 E:519 ||| NNS
on  ||| S:519 E:522 ||| IN
the  ||| S:522 E:526 ||| DT
development  ||| S:526 E:538 ||| NN
of  ||| S:538 E:541 ||| IN
recombinant  ||| S:541 E:553 ||| JJ
thrombopoietins  ||| S:553 E:569 ||| NNS
( ||| S:569 E:570 ||| -LRB-
rhTPO ||| S:570 E:575 ||| NNP
)  ||| S:575 E:577 ||| -RRB-
were  ||| S:577 E:582 ||| VBD
halted  ||| S:582 E:589 ||| VBN
since  ||| S:589 E:595 ||| IN
a  ||| S:595 E:597 ||| DT
minority  ||| S:597 E:606 ||| NN
of  ||| S:606 E:609 ||| IN
patients  ||| S:609 E:618 ||| NNS
developed  ||| S:618 E:628 ||| VBD
an  ||| S:628 E:631 ||| DT
autoantibody  ||| S:631 E:644 ||| NN
that  ||| S:644 E:649 ||| IN
neutralized  ||| S:649 E:661 ||| JJ
pegylated  ||| S:661 E:671 ||| JJ
rhTPO  ||| S:671 E:677 ||| JJ
and  ||| S:677 E:681 ||| CC
also  ||| S:681 E:686 ||| RB
cross-reacted  ||| S:686 E:700 ||| JJ
with  ||| S:700 E:705 ||| IN
and  ||| S:705 E:709 ||| CC
neutralized  ||| S:709 E:721 ||| JJ
endogenous  ||| S:721 E:732 ||| NNS
TPO  ||| S:732 E:736 ||| VBP
resulting  ||| S:736 E:746 ||| VBG
in  ||| S:746 E:749 ||| IN
thrombocytopenia ||| S:749 E:765 ||| NN
.  ||| S:765 E:767 ||| .
Clinical  ||| S:767 E:776 ||| JJ
use  ||| S:776 E:780 ||| NN
of  ||| S:780 E:783 ||| IN
romiplostim ||| S:783 E:794 ||| NN
,  ||| S:794 E:796 ||| ,
a  ||| S:796 E:798 ||| DT
second-generation  ||| S:798 E:816 ||| JJ
TPO-RAs ||| S:816 E:823 ||| NN
,  ||| S:823 E:825 ||| ,
has  ||| S:825 E:829 ||| VBZ
shown  ||| S:829 E:835 ||| VBN
that  ||| S:835 E:840 ||| IN
during  ||| S:840 E:847 ||| IN
long-term  ||| S:847 E:857 ||| JJ
treatment  ||| S:857 E:867 ||| NN
it  ||| S:867 E:870 ||| PRP
may  ||| S:870 E:874 ||| MD
elicit  ||| S:874 E:881 ||| VB
the  ||| S:881 E:885 ||| DT
development  ||| S:885 E:897 ||| NN
of  ||| S:897 E:900 ||| IN
neutralizing  ||| S:900 E:913 ||| JJ
antibodies  ||| S:913 E:924 ||| NNS
to  ||| S:924 E:927 ||| TO
this  ||| S:927 E:932 ||| DT
agent  ||| S:932 E:938 ||| NN
resulting  ||| S:938 E:948 ||| VBG
in  ||| S:948 E:951 ||| IN
acute  ||| S:951 E:957 ||| JJ
thrombocytopenia ||| S:957 E:973 ||| NN
.  ||| S:973 E:975 ||| .
In  ||| S:975 E:978 ||| IN
our  ||| S:978 E:982 ||| PRP$
case  ||| S:982 E:987 ||| NN
series  ||| S:987 E:994 ||| NN
of  ||| S:994 E:997 ||| IN
47  ||| S:997 E:1000 ||| CD
primary  ||| S:1000 E:1008 ||| JJ
adult  ||| S:1008 E:1014 ||| NN
ITP  ||| S:1014 E:1018 ||| NN
patients  ||| S:1018 E:1027 ||| NNS
treated  ||| S:1027 E:1035 ||| VBN
with  ||| S:1035 E:1040 ||| IN
romiplostim ||| S:1040 E:1051 ||| NN
,  ||| S:1051 E:1053 ||| ,
28 ||| S:1053 E:1055 ||| CD
/ ||| S:1055 E:1056 ||| CD
47  ||| S:1056 E:1059 ||| CD
are  ||| S:1059 E:1063 ||| VBP
evaluable  ||| S:1063 E:1073 ||| VBN
for  ||| S:1073 E:1077 ||| IN
response  ||| S:1077 E:1086 ||| NN
loss ||| S:1086 E:1090 ||| NN
.  ||| S:1090 E:1092 ||| .
Among  ||| S:1092 E:1098 ||| IN
these ||| S:1098 E:1103 ||| DT
,  ||| S:1103 E:1105 ||| ,
we  ||| S:1105 E:1108 ||| PRP
observed  ||| S:1108 E:1117 ||| VBD
8  ||| S:1117 E:1119 ||| CD
patients  ||| S:1119 E:1128 ||| NNS
who  ||| S:1128 E:1132 ||| WP
either  ||| S:1132 E:1139 ||| RB
progressively  ||| S:1139 E:1153 ||| RB
( ||| S:1153 E:1154 ||| -LRB-
3 ||| S:1154 E:1155 ||| CD
/ ||| S:1155 E:1156 ||| CD
8 ||| S:1156 E:1157 ||| CD
)  ||| S:1157 E:1159 ||| -RRB-
or  ||| S:1159 E:1162 ||| CC
abruptly  ||| S:1162 E:1171 ||| RB
( ||| S:1171 E:1172 ||| -LRB-
5 ||| S:1172 E:1173 ||| CD
/ ||| S:1173 E:1174 ||| CD
8 ||| S:1174 E:1175 ||| CD
)  ||| S:1175 E:1177 ||| -RRB-
lost  ||| S:1177 E:1182 ||| VBD
response  ||| S:1182 E:1191 ||| NN
which  ||| S:1191 E:1197 ||| WDT
accounts  ||| S:1197 E:1206 ||| VBZ
for  ||| S:1206 E:1210 ||| IN
a  ||| S:1210 E:1212 ||| DT
prevalence  ||| S:1212 E:1223 ||| NN
of  ||| S:1223 E:1226 ||| IN
28,5 ||| S:1226 E:1230 ||| CD
% ||| S:1230 E:1231 ||| NN
.  ||| S:1231 E:1233 ||| .
Neutralizing  ||| S:1233 E:1246 ||| JJ
antibody  ||| S:1246 E:1255 ||| NN
testing  ||| S:1255 E:1263 ||| NN
could  ||| S:1263 E:1269 ||| MD
be  ||| S:1269 E:1272 ||| VB
performed  ||| S:1272 E:1282 ||| VBN
in  ||| S:1282 E:1285 ||| IN
4 ||| S:1285 E:1286 ||| CD
/ ||| S:1286 E:1287 ||| CD
8  ||| S:1287 E:1289 ||| CD
patients  ||| S:1289 E:1298 ||| NNS
and  ||| S:1298 E:1302 ||| CC
3 ||| S:1302 E:1303 ||| CD
/ ||| S:1303 E:1304 ||| CD
4  ||| S:1304 E:1306 ||| CD
tested  ||| S:1306 E:1313 ||| VBN
positive ||| S:1313 E:1321 ||| JJ
.  ||| S:1321 E:1323 ||| .
These  ||| S:1323 E:1329 ||| DT
antibodies  ||| S:1329 E:1340 ||| NNS
did  ||| S:1340 E:1344 ||| VBD
not  ||| S:1344 E:1348 ||| RB
cross-react  ||| S:1348 E:1360 ||| JJ
with  ||| S:1360 E:1365 ||| IN
endogenous  ||| S:1365 E:1376 ||| JJ
TPO  ||| S:1376 E:1380 ||| NNP
and  ||| S:1380 E:1384 ||| CC
re-testing  ||| S:1384 E:1395 ||| JJ
of  ||| S:1395 E:1398 ||| IN
2  ||| S:1398 E:1400 ||| CD
patients  ||| S:1400 E:1409 ||| NNS
at  ||| S:1409 E:1412 ||| IN
9  ||| S:1412 E:1414 ||| CD
and  ||| S:1414 E:1418 ||| CC
7  ||| S:1418 E:1420 ||| CD
months  ||| S:1420 E:1427 ||| NNS
yielded  ||| S:1427 E:1435 ||| VBD
a  ||| S:1435 E:1437 ||| DT
negative  ||| S:1437 E:1446 ||| JJ
result ||| S:1446 E:1452 ||| NN
.  ||| S:1452 E:1454 ||| .
At  ||| S:1454 E:1457 ||| IN
follow-up ||| S:1457 E:1466 ||| NNP
,  ||| S:1466 E:1468 ||| ,
5 ||| S:1468 E:1469 ||| CD
/ ||| S:1469 E:1470 ||| CD
8  ||| S:1470 E:1472 ||| CD
patients  ||| S:1472 E:1481 ||| NNS
-  ||| S:1481 E:1483 ||| :
including  ||| S:1483 E:1493 ||| VBG
the  ||| S:1493 E:1497 ||| DT
3  ||| S:1497 E:1499 ||| CD
patients  ||| S:1499 E:1508 ||| NNS
with  ||| S:1508 E:1513 ||| IN
neutralizing  ||| S:1513 E:1526 ||| JJ
antibodies  ||| S:1526 E:1537 ||| NNS
-  ||| S:1537 E:1539 ||| :
went  ||| S:1539 E:1544 ||| VBD
into  ||| S:1544 E:1549 ||| IN
long-term  ||| S:1549 E:1559 ||| JJ
complete  ||| S:1559 E:1568 ||| JJ
response  ||| S:1568 E:1577 ||| NN
when  ||| S:1577 E:1582 ||| WRB
switched  ||| S:1582 E:1591 ||| VBN
to  ||| S:1591 E:1594 ||| TO
a  ||| S:1594 E:1596 ||| DT
different  ||| S:1596 E:1606 ||| JJ
therapy  ||| S:1606 E:1614 ||| NN
while  ||| S:1614 E:1620 ||| IN
3 ||| S:1620 E:1621 ||| CD
/ ||| S:1621 E:1622 ||| CD
8  ||| S:1622 E:1624 ||| CD
patients  ||| S:1624 E:1633 ||| NNS
never  ||| S:1633 E:1639 ||| RB
regained  ||| S:1639 E:1648 ||| VBD
a  ||| S:1648 E:1650 ||| DT
response  ||| S:1650 E:1659 ||| NN
on  ||| S:1659 E:1662 ||| IN
subsequent  ||| S:1662 E:1673 ||| JJ
lines  ||| S:1673 E:1679 ||| NNS
of  ||| S:1679 E:1682 ||| IN
therapy ||| S:1682 E:1689 ||| NN
.  ||| S:1689 E:1691 ||| .
Response  ||| S:1691 E:1700 ||| NN
loss  ||| S:1700 E:1705 ||| NN
does ||| S:1705 E:1709 ||| VBZ
n't  ||| S:1709 E:1713 ||| RB
seem  ||| S:1713 E:1718 ||| VB
to  ||| S:1718 E:1721 ||| TO
be  ||| S:1721 E:1724 ||| VB
so  ||| S:1724 E:1727 ||| RB
rare  ||| S:1727 E:1732 ||| JJ
an  ||| S:1732 E:1735 ||| DT
event  ||| S:1735 E:1741 ||| NN
during  ||| S:1741 E:1748 ||| IN
romiplostim  ||| S:1748 E:1760 ||| JJ
administration  ||| S:1760 E:1775 ||| NN
( ||| S:1775 E:1776 ||| -LRB-
28.5 ||| S:1776 E:1780 ||| CD
%  ||| S:1780 E:1782 ||| NN
in  ||| S:1782 E:1785 ||| IN
our  ||| S:1785 E:1789 ||| PRP$
series ||| S:1789 E:1795 ||| NN
)  ||| S:1795 E:1797 ||| -RRB-
and  ||| S:1797 E:1801 ||| CC
in  ||| S:1801 E:1804 ||| IN
a  ||| S:1804 E:1806 ||| DT
minority  ||| S:1806 E:1815 ||| NN
of  ||| S:1815 E:1818 ||| IN
patients  ||| S:1818 E:1827 ||| NNS
it  ||| S:1827 E:1830 ||| PRP
can  ||| S:1830 E:1834 ||| MD
be  ||| S:1834 E:1837 ||| VB
associated  ||| S:1837 E:1848 ||| VBN
with  ||| S:1848 E:1853 ||| IN
development  ||| S:1853 E:1865 ||| NN
of  ||| S:1865 E:1868 ||| IN
drug  ||| S:1868 E:1873 ||| NN
neutralizing  ||| S:1873 E:1886 ||| NN
antibodies ||| S:1886 E:1896 ||| NNS
.  ||| S:1896 E:1898 ||| .
Although  ||| S:1898 E:1907 ||| IN
recognised  ||| S:1907 E:1918 ||| NN
by  ||| S:1918 E:1921 ||| IN
the  ||| S:1921 E:1925 ||| DT
manufacturer  ||| S:1925 E:1938 ||| NN
as  ||| S:1938 E:1941 ||| IN
a  ||| S:1941 E:1943 ||| DT
possible  ||| S:1943 E:1952 ||| JJ
adverse  ||| S:1952 E:1960 ||| JJ
event  ||| S:1960 E:1966 ||| NN
ensuing  ||| S:1966 E:1974 ||| VBG
during  ||| S:1974 E:1981 ||| IN
romiplostim  ||| S:1981 E:1993 ||| JJ
administration ||| S:1993 E:2007 ||| NN
,  ||| S:2007 E:2009 ||| ,
development  ||| S:2009 E:2021 ||| NN
of  ||| S:2021 E:2024 ||| IN
neutralizing  ||| S:2024 E:2037 ||| JJ
antibody  ||| S:2037 E:2046 ||| NN
in  ||| S:2046 E:2049 ||| IN
everyday  ||| S:2049 E:2058 ||| JJ
clinical  ||| S:2058 E:2067 ||| JJ
practice  ||| S:2067 E:2076 ||| NN
has  ||| S:2076 E:2080 ||| VBZ
so  ||| S:2080 E:2083 ||| RB
far  ||| S:2083 E:2087 ||| RB
not  ||| S:2087 E:2091 ||| RB
been  ||| S:2091 E:2096 ||| VBN
specifically  ||| S:2096 E:2109 ||| RB
addressed  ||| S:2109 E:2119 ||| VBN
in  ||| S:2119 E:2122 ||| IN
reports  ||| S:2122 E:2130 ||| NNS
on  ||| S:2130 E:2133 ||| IN
romiplostim  ||| S:2133 E:2145 ||| JJ
use  ||| S:2145 E:2149 ||| NN
outside  ||| S:2149 E:2157 ||| IN
controlled  ||| S:2157 E:2168 ||| JJ
studies ||| S:2168 E:2175 ||| NNS
.  ||| S:2175 E:2177 ||| .
Unfortunately ||| S:2177 E:2190 ||| RB
,  ||| S:2190 E:2192 ||| ,
testing  ||| S:2192 E:2200 ||| VBG
for  ||| S:2200 E:2204 ||| IN
these  ||| S:2204 E:2210 ||| DT
antibodies  ||| S:2210 E:2221 ||| NN
requires  ||| S:2221 E:2230 ||| VBZ
adhesion  ||| S:2230 E:2239 ||| VBN
to  ||| S:2239 E:2242 ||| TO
strict  ||| S:2242 E:2249 ||| JJ
procedures  ||| S:2249 E:2260 ||| NNS
which  ||| S:2260 E:2266 ||| WDT
is  ||| S:2266 E:2269 ||| VBZ
not  ||| S:2269 E:2273 ||| RB
easily  ||| S:2273 E:2280 ||| RB
accomplished  ||| S:2280 E:2293 ||| VBN
in  ||| S:2293 E:2296 ||| IN
everyday  ||| S:2296 E:2305 ||| JJ
clinical  ||| S:2305 E:2314 ||| JJ
practice ||| S:2314 E:2322 ||| NN
.  ||| S:2322 E:2324 ||| .
This  ||| S:2324 E:2329 ||| DT
complexity  ||| S:2329 E:2340 ||| NN
represents  ||| S:2340 E:2351 ||| VBZ
a  ||| S:2351 E:2353 ||| DT
significant  ||| S:2353 E:2365 ||| JJ
draw  ||| S:2365 E:2370 ||| NN
back  ||| S:2370 E:2375 ||| RB
in  ||| S:2375 E:2378 ||| IN
extending  ||| S:2378 E:2388 ||| VBG
antibody  ||| S:2388 E:2397 ||| NN
testing  ||| S:2397 E:2405 ||| NN
to  ||| S:2405 E:2408 ||| TO
all  ||| S:2408 E:2412 ||| DT
patients  ||| S:2412 E:2421 ||| NNS
who  ||| S:2421 E:2425 ||| WP
lose  ||| S:2425 E:2430 ||| VBP
response  ||| S:2430 E:2439 ||| NN
to  ||| S:2439 E:2442 ||| TO
romiplostim  ||| S:2442 E:2454 ||| VB
This  ||| S:2454 E:2459 ||| DT
article  ||| S:2459 E:2467 ||| NN
is  ||| S:2467 E:2470 ||| VBZ
protected  ||| S:2470 E:2480 ||| VBN
by  ||| S:2480 E:2483 ||| IN
copyright ||| S:2483 E:2492 ||| NN
.  ||| S:2492 E:2494 ||| .
All  ||| S:2494 E:2498 ||| DT
rights  ||| S:2498 E:2505 ||| NNS
reserved ||| S:2505 E:2513 ||| VBN
.  ||| S:2513 E:2515 ||| .
